2021
Five-Year Outcome in Patients with ESRD Who Received the Bioengineered Human Acellular Vessel for Dialysis Access
Lawson J, Niklason L, Pilgrim A, Kirkton R, Prichard H. Five-Year Outcome in Patients with ESRD Who Received the Bioengineered Human Acellular Vessel for Dialysis Access. Journal Of The American Society Of Nephrology 2021, 32: 232-232. DOI: 10.1681/asn.20213210s1232b.Peer-Reviewed Original Research
2016
Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials
Lawson JH, Glickman MH, Ilzecki M, Jakimowicz T, Jaroszynski A, Peden EK, Pilgrim AJ, Prichard HL, Guziewicz M, Przywara S, Szmidt J, Turek J, Witkiewicz W, Zapotoczny N, Zubilewicz T, Niklason LE. Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials. The Lancet 2016, 387: 2026-2034. PMID: 27203778, PMCID: PMC4915925, DOI: 10.1016/s0140-6736(16)00557-2.Peer-Reviewed Original ResearchConceptsHuman acellular vesselEnd-stage renal diseaseAcellular vesselsPrimary patencySecondary patencyRenal diseaseDialysis accessHaemodialysis accessPhase 2 single-arm trialSingle-arm phase 2 trialPolytetrafluoroethylene arteriovenous graftsPhase 2 trialDialysis access graftsSingle-arm trialArms of patientsPrimary endpointChronic haemodialysisAccess graftsUS National InstitutesArteriovenous graftsVenous anastomosisCensoring eventIntimal hyperplasiaPatencyPatients